At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. (Operator Instructions) Today's conference is being recorded. Thank you. I ...

Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

Mr. Evangelista brings over 30 years of pharmaceutical leadership ... following the acquisition of PPD, David has led global clinical development and laboratory services at PPD and LabCorp ...

The growth of this product has been ideal in that growth ... the company to go after if it was successful with respect to the development of this N-Methyl-d-aspartate receptor [NMDAR] positive ...

PPD, and GSK. His roles have been focused on innovation, operational delivery and advancing global research and development across the pharmaceutical, biotechnology, and medical device sectors.

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.

drowning on and on about how much the team put into the product. The result is that the development team dives in, optimistically, but beneath this optimism lies a quiet risk: Are they building ...

Pharma Tech Industries, a global provider of contract manufacturing and packaging solutions for pharmaceutical, medical ...

Selective Insurance Group, Inc. (NASDAQ:SIGI), a provider of property and casualty insurance products, has recently faced significant challenges in its financial performance, primarily due to reserve ...